Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

Faron Pharmaceuticals Ltd | Belvoir Lettings | Silence Therapeutics PLC | ANGLE PLC | ReNeuron Group PLC

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.


This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.


The event is not suitable for people pursuing commercial opportunities.


RSS Portfolio


ANGLE PLC develops products for use in rare cell diagnostics that enable early, accurate identification of an individual’s condition for the prevention, treatment, and monitoring of disease.

Market: AIM
52-week High/Low: 78.50p / 38.00p
Market Cap: 96.85M

View full company profile

Belvoir Lettings

RSS Portfolio


Founded in 1995 and listed on AIM in 2012 (BLV.L), Belvoir began as a specialist franchised lettings agent and extended its services to encompass estate agency in 2014.  Between 2015 and 2016, the Belvoir Group adopted a multi-brand strategy by acquiring the Newton Fallowell, Goodchilds and Northwood franchise networks.  In 2017 we broadened our property-related services to encompass financial services through the acquisition of Brook Financial Services in 2017 and MAB Glos in 2018, such that we now operate a network of specialist financial advisers providing customers with mortgage and property-related financial services products.
Our 300 property franchisees and 123 financial service advisers operate through 365 individual business units delivering residential lettings and sales, and property-related financial services nationwide.  The Group has a portfolio of 62,780 managed properties, making Belvoir the UK’s largest property franchise group with total revenue of £13.7m.

Market: AIM
52-week High/Low: 123.00p / 85.00p
Market Cap: 41.40M

View full company profile

Faron Pharmaceuticals Ltd

RSS Portfolio


Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.

Market: AIM
52-week High/Low: 166.50p / 50.05p
Market Cap: 31.65M

View full company profile

ReNeuron Group PLC

RSS Portfolio


ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

Market: LSE
52-week High/Low: 325.00p / 29.50p
Market Cap: 89.04M

View full company profile

Silence Therapeutics PLC

RSS Portfolio


Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

Market: AIM
52-week High/Low: 175.00p / 40.00p
Market Cap: 47.29M

View full company profile

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use